{"id":21277,"date":"2023-02-14T17:43:29","date_gmt":"2023-02-14T12:13:29","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=21277"},"modified":"2023-02-14T17:43:31","modified_gmt":"2023-02-14T12:13:31","slug":"pharma-news-for-gsk-roche-aldeyra-iaso-bio","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio","title":{"rendered":"Leo Pharma\u2019s Hand Eczema Clinical Trial Updates; GSK&#8217;s PD-1 inhibitor Jemperli Approval; Roche Announces Phase III Result of Vabysmo; FDA Accepts NDA for Aldeyra\u2019s reproxalap; RMAT and Fast Track Designations to IASO Bio\u2019s CT103A; Orphan Drug Designation to Jubilant Therapeutics\u2019s JBI-778"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fad54d9dc6a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fad54d9dc6a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\/#Leo_Pharma_Announces_Positive_Results_of_Phase_III_Hand_Eczema_Clinical_Trial\" >Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\/#FDA_Approves_GSKs_PD-1_inhibitor_Jemperli\" >FDA Approves GSK&#8217;s PD-1 inhibitor Jemperli<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\/#Regenerative_Medicine_Advanced_Therapy_RMAT_and_FDA_Fast_Track_Designations_to_IASO_Bios_CT103A\" >Regenerative Medicine Advanced Therapy (RMAT) and FDA Fast Track Designations to IASO Bio\u2019s CT103A<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\/#Jubilant_Therapeutics_Receives_Orphan_Drug_Designation_for_its_Drug_JBI-778_to_Treat_Glioblastoma_Multiforme_GBM\" >Jubilant Therapeutics Receives Orphan Drug Designation for its Drug, JBI-778, to Treat Glioblastoma Multiforme (GBM)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\/#Roche_Announces_Positive_New_Phase_III_Data_Vabysmo_in_RVO\" >Roche Announces Positive New Phase III Data Vabysmo in RVO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\/#FDA_Accepts_NDA_for_Aldeyras_reproxalap_for_Dry_Eye_Disease\" >FDA Accepts NDA for Aldeyra\u2019s reproxalap for Dry Eye Disease<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-leo-pharma-announces-positive-results-of-phase-iii-hand-eczema-clinical-trial\"><span class=\"ez-toc-section\" id=\"Leo_Pharma_Announces_Positive_Results_of_Phase_III_Hand_Eczema_Clinical_Trial\"><\/span><strong>Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>LEO Pharma A\/S<\/strong>, a global leader in medical dermatology, announced that the <strong>DELTA 2 trial<\/strong> yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving <strong>delgocitinib <\/strong>cream, an investigational topical pan-Janus kinase (JAK) inhibitor, for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hand-eczema-market\">treatment of adults with moderate to severe chronic hand eczema (CHE)<\/a>.<\/p>\n\n\n\n<p>The trial&#8217;s primary endpoint was met with a statistically significant improvement in CHE after 16 weeks of treatment with delgocitinib cream versus cream vehicle, and the treatment was well tolerated. When compared to subjects treated with cream vehicle, patients treated with delgocitinib cream had a significantly higher proportion of their <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hand-eczema-market\">CHE signs and symptoms<\/a> cleared early in the treatment period. DELTA 2 is the second phase III trial to achieve all key secondary endpoints and confirm the positive results of DELTA 1.<\/p>\n\n\n\n<p>&#8220;It&#8217;s incredibly exciting to see the level of consistency that our DELTA 2 results show, especially in light of the positive DELTA 1 results announced late last year,&#8221; said <strong>J\u00f6rg M\u00f6ller, Executive Vice President, Global Research &amp; Development, LEO Pharma.<\/strong> &#8220;We know that CHE can have a significant negative impact on a patient&#8217;s quality of life, physical functioning, and ability to work. These findings move us one step closer to establishing delgocitinib as a best-in-class innovative topical treatment for patients suffering from this difficult-to-treat disease.&#8221;<\/p>\n\n\n\n<p>Subjects who completed 16 weeks of treatment in <strong>DELTA 1 or DELTA 2 trials<\/strong> were invited to participate in the DELTA 3 extension trial to assess the long-term effects of delgocitinib cream. 2 The data set will be further analyzed to determine the full potential of delgocitinib cream in the treatment of adults with moderate to severe CHE. DELTA 2 detailed results will be submitted for scientific presentation and publication at a later date.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Approves_GSKs_PD-1_inhibitor_Jemperli\"><\/span><strong>FDA Approves GSK&#8217;s PD-1 inhibitor Jemperli<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>GSK plc<\/strong> announced that the US Food and Drug Administration (FDA) had granted full approval to <strong>Jemperli (dostarlimab-gxly)<\/strong> for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, who have progressed on or after a prior platinum-containing regimen and are not candidates for curative surgery or radiation.<\/p>\n\n\n\n<p>&#8220;This US regulatory action confirms our confidence in Jemperli as an important treatment option for patients with dMMR recurrent or advanced endometrial cancer,&#8221; said <strong>Hesham Abdullah, Senior Vice President, Global Head of Oncology Development at GSK.<\/strong> We continue to harness Jemperli&#8217;s potential as the foundation for our immuno-oncology development programs to address unmet patient needs, including earlier lines of endometrial cancer and other solid tumors.&#8221;<\/p>\n\n\n\n<p><strong>Jemperli <\/strong>was granted accelerated approval in April 2021 for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/endometrial-cancer-market\">treatment of adult patients with dMMR recurrent or advanced endometrial cancer<\/a> that had progressed on or after prior treatment with a platinum-containing regimen. This approval is based on additional data from the ongoing <strong>GARNET trial&#8217;s <\/strong>A1 expansion cohort, which is a phase I, multicenter, open-label, single-arm study of Jemperli monotherapy in patients with advanced or recurrent solid tumors. Cohort A1 looked at Jemperli&#8217;s efficacy in <strong>141 patients <\/strong>with dMMR advanced or recurrent endometrial cancer who had progressed on or after prior treatment with a platinum-containing regimen.<\/p>\n\n\n\n<p>Overall response rate (ORR) and duration of response (DOR) were the primary efficacy outcome measures, as determined by a blinded independent central review using RECIST v1.1. The confirmed ORR was <strong>45.4%<\/strong> (95% CI: 37.0, 54.0), with a complete response rate of <strong>15.6%<\/strong> and a partial response rate of <strong>29.8%.<\/strong> The median DOR (measured from the time of first response) was not reached (range: 1.2+, 52.8+ months), with <strong>85.9% <\/strong>of patients having a duration of 12 months and <strong>54.7%<\/strong> having a duration of 24 months. The median duration of response was 27.9 months.<\/p>\n\n\n\n<p>Treatment-related adverse events for cohort A1 were consistent with previous analyses. Fatigue\/asthenia, anemia, rash, nausea, diarrhea, constipation, and vomiting were the most common adverse reactions (20%). Anemia, increased transaminases, urinary tract infection, fatigue\/asthenia, and diarrhea were the most common Grade 3 or 4 adverse reactions (2%).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regenerative_Medicine_Advanced_Therapy_RMAT_and_FDA_Fast_Track_Designations_to_IASO_Bios_CT103A\"><\/span><strong>Regenerative Medicine Advanced Therapy (RMAT) and FDA Fast Track Designations to IASO Bio\u2019s CT103A<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On Feb. 12, 2023, IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced that the U.S. Food and Drug Administration (FDA) had granted both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track (FT) designation to its investigational new drug BCMA CAR-T CT103A (Equecabtagene Autoleucel) for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight\"><strong>treatment of relapsed\/refractory Multiple Myeloma (RRMM)<\/strong><\/a>. IASO Bio and Innovent Biologics, Inc. (1801.HK) are jointly developing equecabtagene autoleucel for the treatment of RRMM in mainland China.<\/p>\n\n\n\n<p>IASO Bio\u2019s Equecabtagene autoleucel (CT103A) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane, 4-1BB co-stimulatory and CD3\u03b6 activation domains. Based on strict selection and screening, utilizing a proprietary in-house optimization platform, and integrated in-house manufacturing process improvement, the construct of CT103A is potent and shows prolonged persistency in patients.&nbsp;<\/p>\n\n\n\n<p>The NMPA accepted the New Drug Application for equecabtagene autoleucel for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-multiple-myeloma-market\"><strong>treatment of relapsed\/refractory multiple myeloma (RRMM)<\/strong><\/a>. Earlier in February 2021, Equecabtagene autoleucel also received Breakthrough Therapy Designation by the NMPA, and later on, in February 2022, it received Orphan Drug Designation (ODD). Similarly, in December 2022, U.S. FDA granted IND approval to Equecabtagene autoleucel. Moreover, as per the update from the IASO Bio, in addition to multiple myeloma, the NMPA has approved the IND application of equecabtagene autoleucel for the new expanded indication of Neuromyelitis Optica Spectrum Disorder (NMOSD).<\/p>\n\n\n\n<p>Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. It is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people.&nbsp;<\/p>\n\n\n\n<p>As per DelveInsight, in the year 2020, the total number of <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-epidemiology-forecast-insight\"><strong>incident cases of Multiple Myeloma<\/strong><\/a> was 91,693 cases in the 8MM (i.e., the United States, EU4 (Spain, Germany, France, and Italy), the UK, Japan, and China. In the United States, there were 32,270 cases of Multiple Myeloma (the highest number among the 8MM) in 2020. China reported the second-highest incident cases of Multiple myeloma, i.e., 21,116, which accounted for nearly 23% of the total 8MM cases in the year 2020. In relapsed\/refractory MM (RRMM), cancer returns after treatment or after a period of remission. Refractory multiple myeloma refers to cancer that is not responding to standard therapy. There are many potential mechanisms that may impact and promote treatment resistance. The development of emerging therapies like CT103A, and others, holds immense potential to improve the relapsed\/refractory MM (RRMM) treatment scenario.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Jubilant_Therapeutics_Receives_Orphan_Drug_Designation_for_its_Drug_JBI-778_to_Treat_Glioblastoma_Multiforme_GBM\"><\/span><strong>Jubilant Therapeutics Receives Orphan Drug Designation for its Drug, JBI-778, to Treat Glioblastoma Multiforme (GBM)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On February 13, 2023, Jubilant Therapeutics Inc. announced that the United States Food and Drug Administration (US FDA) had granted Orphan Drug Designation (ODD) for JBI-778 for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-market\"><strong>treatment of Glioblastoma Multiforme (GBM)<\/strong><\/a>. Jubilant Therapeutics\u2019s JBI-778 is an oral, brain penetrant, and substrate-competitive protein arginine methyl transferase 5 (PRMT5) inhibitor for treating tumors with brain metastases and primary brain tumors, including high-grade glioma.&nbsp;<\/p>\n\n\n\n<p>The drug has a unique mechanism of action compared to existing PRMT5 inhibitors by being substrate-competitive and S-adenosylmethionine (SAM) cooperative, combined with a high brain exposure that enables targeting of both primary brain tumors and CNS metastasis.&nbsp;<\/p>\n\n\n\n<p>Syed Kazmi, Chief Executive Officer of Jubilant Therapeutics Inc., has said, &#8220;JBI-778&#8217;s differentiated profile compared to other PRMT5 inhibitors in development addresses safety issues of first-generation PRMT5 inhibitors. It also enables a balanced exposure in the brain and plasma &#8211; for the treatment of GBM and brain metastases along with the systemic disease. We have identified a novel synthetic lethality approach for prospective patient selection in target indications. JBI-778 has already been cleared by the US FDA to initiate clinical trials, which we anticipate to start during the second half of 2023.&#8221;<\/p>\n\n\n\n<p>As per DelveInsight, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-epidemiology-forecast\"><strong>diagnosed incident population of Glioblastoma<\/strong><\/a> in the 7MM was 32,546 cases in 2021 and is projected to increase in the coming years. Among the EU-4, the UK countries, Germany accounted for the highest number of Glioblastoma cases, followed by France, whereas Spain accounted for the lowest number of cases in 2021. There are several emerging therapies under development to <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-pipeline-insight\"><strong>treat Glioblastoma Multiforme<\/strong><\/a>. The approval and the launch of emerging therapies, including JBI-778, among others, hold immense potential to improve the Glioblastoma Multiforme treatment scenario in the coming years. JBI-778 has a unique opportunity to address the unmet needs of patients with an enhanced therapeutic index.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche_Announces_Positive_New_Phase_III_Data_Vabysmo_in_RVO\"><\/span><strong>Roche Announces Positive New Phase III Data Vabysmo in RVO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Roche <\/strong>declared positive new data from two global <strong>phase III studies<\/strong>, <strong>BALATON <\/strong>and <strong>COMINO<\/strong>, evaluating <strong>Vabysmo <\/strong>(<strong>faricimab<\/strong>) in <a href=\"https:\/\/www.delveinsight.com\/report-store\/macular-edema-me-market\"><strong>macular edema<\/strong><\/a> due to branch and <a href=\"https:\/\/www.delveinsight.com\/report-store\/central-retinal-vein-occlusion-market\"><strong>central retinal vein occlusion<\/strong><\/a> at <strong>24 weeks<\/strong>. According to the studies, Vabysmo treatment produced early and long-lasting vision improvements and met the primary outcome of non-inferior visual acuity gains compared to treatment with <strong>aflibercept<\/strong>.<\/p>\n\n\n\n<p>Reduced central subfield thickness, a measure of retinal fluid drying from baseline, was another indication of vabysmo&#8217;s effectiveness. Vabysmo&#8217;s safety profile matched that of earlier studies. The Bascom Palmer Eye Institute in Florida, United States, is hosting Angiogenesis, Exudation, and Degeneration 2023, where the results will be virtually presented on February 11.<\/p>\n\n\n\n<p>Around <strong>70 million<\/strong> people worldwide are affected by <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinal-vein-occlusion-market\"><strong>retinal vein occlusion<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-macular-edema-dme-market\"><strong>diabetic macular edema<\/strong><\/a>, and neovascular or<a href=\"https:\/\/www.delveinsight.com\/report-store\/wet-age-related-macular-degeneration-wet-amd-market\"><strong> wet age-related macular degeneration<\/strong><\/a>, which are three of the main causes of vision loss. Data from the BALATON and COMINO studies will be submitted to health agencies around the world, including the <strong>European Medicines Agency<\/strong> and the <strong>US Food and Drug Administration<\/strong>, for clearance to treat macular edema brought on by RVO. This would be Vabysmo&#8217;s third indication; it is already permitted in more than 50 countries to treat diabetic macular edema and non-AMD macular edema.<\/p>\n\n\n\n<p>The effectiveness and safety of vabysmo in treating nAMD and DME have been proven by two-year data from four major, global studies with more than <strong>3,000<\/strong> participants. With <strong>phase III trials<\/strong> showing treatment intervals of up to four months for persons with these problems, Vabysmo is the first bispecific antibody approved for the eye. It targets and blocks angiopoietin-2 and vascular endothelial growth factor-A, two signalling pathways associated with a number of retinal disorders that can cause blindness. To treat these conditions, more than<strong> 450,000 Vabysmo doses<\/strong> have been given out globally.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Accepts_NDA_for_Aldeyras_reproxalap_for_Dry_Eye_Disease\"><\/span><strong>FDA Accepts NDA for Aldeyra\u2019s reproxalap for Dry Eye Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Aldeyra Therapeutics<\/strong> declared that the U.S. Food and Drug Administration had accepted the New Drug Application for <strong>topical ocular reproxalap<\/strong>, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-eye-disease-market-insights\"><strong>dry eye disease<\/strong><\/a>. The FDA assigned a <strong>Prescription Drug User Fee Act date of November 23, 2023<\/strong>. The FDA noted that no potential filing review issues have been identified and that an advisory committee meeting is not currently planned.<\/p>\n\n\n\n<p>The NDA is supported by previously reported safety and efficacy results from five appropriate and well-controlled clinical trials that included information for the <strong>Schirmer test, Schirmer test 10 mm responder analysis, ocular dryness symptom score<\/strong>, and<strong> ocular redness<\/strong>. The NDA contains information on action starting minutes after medication administration and lasting up to 12 weeks, crossover and parallel-group clinical trial designs, and evaluation in dry eye chamber challenge and real-world situations.&nbsp;More than <strong>2,000 participants<\/strong> have received topical ocular reproxalap studies, and there have been no clinically relevant safety issues noted. Mild and temporary instillation site irritation is the most often reported adverse event in clinical trials.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A\/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical pan-Janus kinase (JAK) inhibitor, for the treatment [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":21281,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":7,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1678,7521,18957,1787,16690,903,20353,20355,2218,410,20354,16762,524],"industry":[17226],"therapeutic_areas":[17237,17245,17228,17244],"class_list":["post-21277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-aldeyra-therapeutics","tag-chronic-hand-eczema","tag-dry-eye-disease","tag-glioblastoma","tag-glioblastoma-multiforme","tag-gsk","tag-iaso-bio","tag-jubilant-therapeutics","tag-leo-pharma","tag-multiple-myeloma","tag-relapsed-refractory-multiple-myeloma","tag-retinal-vein-occlusion","tag-roche","industry-medical-devices","therapeutic_areas-dermatology","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Leo Pharma, GSK, Roche, Aldeyra, IASO Bio<\/title>\n<meta name=\"description\" content=\"Leo Pharma\u2019s delgocitinib; GSK&#039;s Jemperli; Roche&#039;s Vabysmo trial; Aldeyra\u2019s reproxalap; IASO Bio\u2019s CT103A; Jubilant Therapeutics\u2019s JBI-778\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Leo Pharma, GSK, Roche, Aldeyra, IASO Bio\" \/>\n<meta property=\"og:description\" content=\"Leo Pharma\u2019s delgocitinib; GSK&#039;s Jemperli; Roche&#039;s Vabysmo trial; Aldeyra\u2019s reproxalap; IASO Bio\u2019s CT103A; Jubilant Therapeutics\u2019s JBI-778\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-14T12:13:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-14T12:13:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/02\/14150007\/Pharma-News-and-Updates-for-Leo-Pharma-GSK-Roche-Aldeyra-IASO-Bio.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Leo Pharma, GSK, Roche, Aldeyra, IASO Bio","description":"Leo Pharma\u2019s delgocitinib; GSK's Jemperli; Roche's Vabysmo trial; Aldeyra\u2019s reproxalap; IASO Bio\u2019s CT103A; Jubilant Therapeutics\u2019s JBI-778","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Leo Pharma, GSK, Roche, Aldeyra, IASO Bio","og_description":"Leo Pharma\u2019s delgocitinib; GSK's Jemperli; Roche's Vabysmo trial; Aldeyra\u2019s reproxalap; IASO Bio\u2019s CT103A; Jubilant Therapeutics\u2019s JBI-778","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-02-14T12:13:29+00:00","article_modified_time":"2023-02-14T12:13:31+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/02\/14150007\/Pharma-News-and-Updates-for-Leo-Pharma-GSK-Roche-Aldeyra-IASO-Bio.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio","name":"Pharma News | Leo Pharma, GSK, Roche, Aldeyra, IASO Bio","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/02\/14150007\/Pharma-News-and-Updates-for-Leo-Pharma-GSK-Roche-Aldeyra-IASO-Bio.png","datePublished":"2023-02-14T12:13:29+00:00","dateModified":"2023-02-14T12:13:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Leo Pharma\u2019s delgocitinib; GSK's Jemperli; Roche's Vabysmo trial; Aldeyra\u2019s reproxalap; IASO Bio\u2019s CT103A; Jubilant Therapeutics\u2019s JBI-778","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gsk-roche-aldeyra-iaso-bio#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/02\/14150007\/Pharma-News-and-Updates-for-Leo-Pharma-GSK-Roche-Aldeyra-IASO-Bio.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/02\/14150007\/Pharma-News-and-Updates-for-Leo-Pharma-GSK-Roche-Aldeyra-IASO-Bio.png","width":772,"height":482,"caption":"Pharma News and Updates for Leo Pharma, GSK, Roche, Aldeyra, IASO Bio"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/02\/14150007\/Pharma-News-and-Updates-for-Leo-Pharma-GSK-Roche-Aldeyra-IASO-Bio-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aldeyra Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic hand eczema<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dry Eye disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">glioblastoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Glioblastoma multiforme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IASO Bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Jubilant Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">LEO Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Relapsed\/Refractory Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinal vein occlusion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aldeyra Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Chronic hand eczema<\/span>","<span class=\"advgb-post-tax-term\">Dry Eye disease<\/span>","<span class=\"advgb-post-tax-term\">glioblastoma<\/span>","<span class=\"advgb-post-tax-term\">Glioblastoma multiforme<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">IASO Bio<\/span>","<span class=\"advgb-post-tax-term\">Jubilant Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">LEO Pharma<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Relapsed\/Refractory Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Retinal vein occlusion<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Feb 14, 2023","modified":"Updated on Feb 14, 2023"},"absolute_dates_time":{"created":"Posted on Feb 14, 2023 5:43 pm","modified":"Updated on Feb 14, 2023 5:43 pm"},"featured_img_caption":"Pharma News and Updates for Leo Pharma, GSK, Roche, Aldeyra, IASO Bio","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=21277"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/21281"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=21277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=21277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=21277"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=21277"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=21277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}